Eikonizo Therapeutics
Developing therapies to improve the treatment of human disease, specifically neurodegenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Related Content
Eikonizo Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. The company specializes in creating brain-penetrant small molecules that inhibit HDAC6, an enzyme implicated in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). By targeting HDAC6, Eikonizo aims to preserve axonal transport and reduce protein aggregates, thereby slowing or halting disease progression.
Eikonizo operates in the biopharmaceutical market, serving patients suffering from neurodegenerative disorders. The company's business model revolves around research and development (R&D) of novel therapeutics, which are then brought to market through clinical trials and regulatory approval processes. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved therapies.
Keywords: neurodegenerative, HDAC6 inhibitor, brain-penetrant, ALS, Alzheimer's, axonal transport, protein aggregates, biopharmaceutical, R&D, therapeutic development.